CN103442767A - 药物活性物质的固体形式 - Google Patents

药物活性物质的固体形式 Download PDF

Info

Publication number
CN103442767A
CN103442767A CN2012800097909A CN201280009790A CN103442767A CN 103442767 A CN103442767 A CN 103442767A CN 2012800097909 A CN2012800097909 A CN 2012800097909A CN 201280009790 A CN201280009790 A CN 201280009790A CN 103442767 A CN103442767 A CN 103442767A
Authority
CN
China
Prior art keywords
degrees
solid form
ray powder
powder diffraction
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012800097909A
Other languages
English (en)
Chinese (zh)
Inventor
R·迪度恩
K·海因里希
P·N·阿布拉汉姆
S-M·邝
G·C·维索
B·赵
U·施威特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Plexxikon Inc
Original Assignee
F Hoffmann La Roche AG
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Plexxikon Inc filed Critical F Hoffmann La Roche AG
Priority to CN201610829679.4A priority Critical patent/CN106632314A/zh
Publication of CN103442767A publication Critical patent/CN103442767A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2012800097909A 2011-02-21 2012-02-21 药物活性物质的固体形式 Pending CN103442767A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610829679.4A CN106632314A (zh) 2011-02-21 2012-02-21 药物活性物质的固体形式

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161444866P 2011-02-21 2011-02-21
US61/444,866 2011-02-21
PCT/US2012/025965 WO2012161776A1 (en) 2011-02-21 2012-02-21 Solid forms of a pharmaceutically active substance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610829679.4A Division CN106632314A (zh) 2011-02-21 2012-02-21 药物活性物质的固体形式

Publications (1)

Publication Number Publication Date
CN103442767A true CN103442767A (zh) 2013-12-11

Family

ID=47217568

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610829679.4A Pending CN106632314A (zh) 2011-02-21 2012-02-21 药物活性物质的固体形式
CN2012800097909A Pending CN103442767A (zh) 2011-02-21 2012-02-21 药物活性物质的固体形式

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610829679.4A Pending CN106632314A (zh) 2011-02-21 2012-02-21 药物活性物质的固体形式

Country Status (17)

Country Link
US (1) US8865735B2 (enExample)
EP (2) EP2678075A4 (enExample)
JP (2) JP2014505740A (enExample)
KR (1) KR20140011340A (enExample)
CN (2) CN106632314A (enExample)
AR (1) AR085279A1 (enExample)
AU (1) AU2012259422B2 (enExample)
BR (1) BR112013021103A2 (enExample)
CA (1) CA2827708A1 (enExample)
IL (1) IL227862A0 (enExample)
MX (1) MX2013009558A (enExample)
MY (1) MY163083A (enExample)
RU (1) RU2013143010A (enExample)
SG (1) SG192722A1 (enExample)
TW (1) TWI558702B (enExample)
WO (1) WO2012161776A1 (enExample)
ZA (1) ZA201306237B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115991704A (zh) * 2022-12-16 2023-04-21 深圳市新阳唯康科技有限公司 维莫非尼的新晶型、使用新晶型制备的活性药物和药物组合物

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
MX2012005284A (es) 2009-11-06 2012-06-28 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas. e indicaciones para ello.
CN102740698A (zh) 2009-11-18 2012-10-17 普莱希科公司 用于激酶调节的化合物和方法及其适应症
BR112012015745A2 (pt) 2009-12-23 2016-05-17 Plexxikon Inc compostos e métodos para a modulação de quinase, e indicações dos mesmos
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
SG194847A1 (en) 2011-05-17 2013-12-30 Plexxikon Inc Kinase modulation and indications therefor
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JP2015522037A (ja) * 2012-07-03 2015-08-03 ラシオファルム ゲーエムベーハー ベムラフェニブコリン塩の固体形態
BR112015003418A2 (pt) 2012-08-17 2017-07-04 Hoffmann La Roche produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica.
WO2014039714A2 (en) 2012-09-06 2014-03-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2895239C (en) 2012-12-21 2020-10-27 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9440971B2 (en) 2013-03-14 2016-09-13 Ratiopharm Gmbh Solid state forms of vemurafenib hydrochloride
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2014145051A1 (en) 2013-03-15 2014-09-18 Jiazhong Zhang Heterocyclic compounds and uses thereof
BR112015028845A2 (pt) 2013-05-30 2017-07-25 Plexxikon Inc compostos para a modulação da quinase e indicações da mesma
CZ2013943A3 (cs) 2013-11-27 2015-06-03 Zentiva, K.S. Krystalické formy vemurafenibu
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2016044067A1 (en) 2014-09-15 2016-03-24 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2016083956A1 (en) 2014-11-29 2016-06-02 Shilpa Medicare Limited Substantially pure vemurafenib and its salts
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CZ2015250A3 (cs) 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
HRP20201383T1 (hr) 2015-05-06 2020-11-27 Plexxikon Inc. Kruti oblici spoja za moduliranje kinaza
BR112017023540B1 (pt) 2015-05-06 2023-04-04 Plexxikon, Inc. Processos de preparação de derivados de 1h-pirrolo[2,3-b]piridina que modulam quinases
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3353179B1 (en) 2015-09-21 2022-02-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
WO2017100201A1 (en) 2015-12-07 2017-06-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2017098336A1 (en) * 2015-12-11 2017-06-15 Laurus Labs Private Limited Novel polymorphs of vemurafenib, process for its preparation and pharmaceutical composition thereof
ES2904615T3 (es) 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ido及tdo調節之化合物及方法以及其適應症
WO2018136202A2 (en) 2016-12-23 2018-07-26 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
CA3056777A1 (en) 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
TWI805599B (zh) 2017-07-25 2023-06-21 美商第一三共公司 激酶調節化合物之調配物
NL2019807B1 (en) 2017-10-26 2019-05-06 Boston Scient Scimed Inc Shockwave generating device
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
TWI803530B (zh) * 2017-10-27 2023-06-01 美商普雷辛肯公司 調節激酶之化合物之調配物
WO2019183145A1 (en) 2018-03-20 2019-09-26 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
AU2020271836B2 (en) 2019-04-09 2025-11-13 Opna Bio SA Condensed azines for EP300 or CBP modulation and indications therefor
WO2020256898A1 (en) 2019-06-19 2020-12-24 Boston Scientific Scimed, Inc. Balloon surface photoacoustic pressure wave generation to disrupt vascular lesions
US12402946B2 (en) 2019-06-19 2025-09-02 Boston Scientific Scimed, Inc. Breakdown of laser pulse energy for breakup of vascular calcium
US11717139B2 (en) 2019-06-19 2023-08-08 Bolt Medical, Inc. Plasma creation via nonaqueous optical breakdown of laser pulse energy for breakup of vascular calcium
US11660427B2 (en) 2019-06-24 2023-05-30 Boston Scientific Scimed, Inc. Superheating system for inertial impulse generation to disrupt vascular lesions
US20200406010A1 (en) 2019-06-26 2020-12-31 Boston Scientific Scimed, Inc. Side light direction plasma system to disrupt vascular lesions
US11583339B2 (en) 2019-10-31 2023-02-21 Bolt Medical, Inc. Asymmetrical balloon for intravascular lithotripsy device and method
US12102384B2 (en) 2019-11-13 2024-10-01 Bolt Medical, Inc. Dynamic intravascular lithotripsy device with movable energy guide
US12274497B2 (en) 2019-12-18 2025-04-15 Bolt Medical, Inc. Multiplexer for laser-driven intravascular lithotripsy device
US12446961B2 (en) 2020-02-10 2025-10-21 Bolt Medical, Inc. System and method for pressure monitoring within a catheter system
US11672599B2 (en) 2020-03-09 2023-06-13 Bolt Medical, Inc. Acoustic performance monitoring system and method within intravascular lithotripsy device
US20210290286A1 (en) 2020-03-18 2021-09-23 Bolt Medical, Inc. Optical analyzer assembly and method for intravascular lithotripsy device
US11707323B2 (en) 2020-04-03 2023-07-25 Bolt Medical, Inc. Electrical analyzer assembly for intravascular lithotripsy device
AU2021261383A1 (en) 2020-04-23 2022-11-17 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
EP4143168A1 (en) 2020-04-29 2023-03-08 Plexxikon Inc. Synthesis of heterocyclic compounds
US12295654B2 (en) 2020-06-03 2025-05-13 Boston Scientific Scimed, Inc. System and method for maintaining balloon integrity within intravascular lithotripsy device with plasma generator
US12207870B2 (en) 2020-06-15 2025-01-28 Boston Scientific Scimed, Inc. Spectroscopic tissue identification for balloon intravascular lithotripsy guidance
JP2023542473A (ja) 2020-08-21 2023-10-10 プレキシコン インコーポレーテッド 併用薬抗がん治療
US12016610B2 (en) 2020-12-11 2024-06-25 Bolt Medical, Inc. Catheter system for valvuloplasty procedure
EP4277548B1 (en) 2021-01-12 2025-06-04 Bolt Medical, Inc. Balloon assembly for valvuloplasty catheter system
US11672585B2 (en) 2021-01-12 2023-06-13 Bolt Medical, Inc. Balloon assembly for valvuloplasty catheter system
US11648057B2 (en) 2021-05-10 2023-05-16 Bolt Medical, Inc. Optical analyzer assembly with safety shutdown system for intravascular lithotripsy device
US11806075B2 (en) 2021-06-07 2023-11-07 Bolt Medical, Inc. Active alignment system and method for laser optical coupling
US11839391B2 (en) 2021-12-14 2023-12-12 Bolt Medical, Inc. Optical emitter housing assembly for intravascular lithotripsy device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114928A2 (en) * 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions and uses thereof

Family Cites Families (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2234705A (en) 1940-04-12 1941-03-11 Eastman Kodak Co Cellulose organic derivative composition containing esters of monoalkoxy benzoic acids
US2413258A (en) 1942-07-07 1946-12-24 United Gas Improvement Co Polystyrene-type resins plasticized with high boiling fatty acid alkyl esters
FR1579473A (enExample) 1966-10-21 1969-08-29
DE2413258A1 (de) 1974-03-20 1975-10-02 Bayer Ag Alkoxycarbonylphenylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als herbizide
AU7915675A (en) 1974-03-20 1976-09-23 Bayer Ag Alkoxycarbonylphenylureas
GB1573212A (en) 1976-04-15 1980-08-20 Technicon Instr Immunoassay for gentamicin
US4664504A (en) 1983-01-20 1987-05-12 Tokyo Shibaura Denki Kabushiki Kaisha Image forming apparatus
US4568649A (en) 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US4626513A (en) 1983-11-10 1986-12-02 Massachusetts General Hospital Method and apparatus for ligand detection
AU567140B2 (en) 1984-01-06 1987-11-12 Shionogi & Co., Ltd. Sulphonamido-benzamide derivatives
DE3483099D1 (de) 1984-03-15 1990-10-04 Immunex Corp Test zur sofortigen feststellung von liganden, testsatz und seine herstellung.
IT1196133B (it) 1984-06-06 1988-11-10 Ausonia Farma Srl Derivati furanici con attivita' antiulcera
US4714693A (en) 1986-04-03 1987-12-22 Uop Inc. Method of making a catalyst composition comprising uniform size metal components on carrier
DE3642315A1 (de) 1986-12-11 1988-06-23 Boehringer Mannheim Gmbh Neue pyrrolobenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel
US5688655A (en) 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5658775A (en) 1988-05-17 1997-08-19 Sloan-Kettering Institute For Cancer Research Double copy retroviral vector
JP2528706B2 (ja) 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
DE4022414A1 (de) 1990-07-13 1992-01-16 Bayer Ag Substituierte pyrrolo-pyridine
DE69222847T3 (de) 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
JPH06509578A (ja) 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5632957A (en) 1993-11-01 1997-05-27 Nanogen Molecular biological diagnostic systems including electrodes
GB9127531D0 (en) 1991-12-31 1992-02-19 Fujisawa Pharmaceutical Co Heterocyclic compound
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JPH05236997A (ja) 1992-02-28 1993-09-17 Hitachi Ltd ポリヌクレオチド捕捉用チップ
JPH06135946A (ja) 1992-10-30 1994-05-17 Otsuka Pharmaceut Co Ltd ピラジン誘導体
AU686115B2 (en) 1992-11-02 1998-02-05 Fujisawa Pharmaceutical Co., Ltd. Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
NZ261593A (en) 1993-03-01 1996-09-25 Merck Sharp & Dohme 3-piperazinylmethly-1h-indolopyridine derivatives and pharmaceutical compositions
ES2134929T3 (es) 1993-03-01 1999-10-16 Merck Sharp & Dohme Derivados de pirrolo-piridina como ligandos para receptores de dopamina.
CA2156410A1 (en) 1993-03-01 1994-09-15 Raymond Baker Pyrrolo-pyridine derivatives
US5576319A (en) 1993-03-01 1996-11-19 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
AU686186B2 (en) 1993-05-27 1998-02-05 Aventisub Ii Inc. Topologically segregated, encoded solid phase libraries
US5840485A (en) 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
IT1265057B1 (it) 1993-08-05 1996-10-28 Dompe Spa Tropil 7-azaindolil-3-carbossiamidi
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
GB9319297D0 (en) 1993-09-17 1993-11-03 Wellcome Found Indole derivatives
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6468742B2 (en) 1993-11-01 2002-10-22 Nanogen, Inc. Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip
US5965452A (en) 1996-07-09 1999-10-12 Nanogen, Inc. Multiplexed active biologic array
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
GB9408577D0 (en) 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
US5763198A (en) 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
GB9416189D0 (en) 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
EP0775138B1 (en) 1994-08-10 2000-02-23 MERCK SHARP & DOHME LTD. TETRAHYDROPYRIDINYLMETHYL DERIVATIVES OF PYRROLO 2,3-b]PYRIDINE
GB9416162D0 (en) 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5837815A (en) 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
GB9503400D0 (en) 1995-02-21 1995-04-12 Merck Sharp & Dohme Therpeutic agents
GB2298199A (en) 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
US5959098A (en) 1996-04-17 1999-09-28 Affymetrix, Inc. Substrate preparation process
US6117681A (en) 1995-03-29 2000-09-12 Bavarian Nordic Research Inst. A/S Pseudotyped retroviral particles
GB9507291D0 (en) 1995-04-07 1995-05-31 Merck Sharp & Dohme Therapeutic agents
GB2299581A (en) 1995-04-07 1996-10-09 Merck Sharp & Dohme 3-(Tetrahydropyridin-1-yl-methyl)pyrrolo[2,3-b]pyridine derivatives as ligands for dopamine receptor subtypes
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US5866411A (en) 1995-09-08 1999-02-02 Pedersen; Finn Skou Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector
US5747276A (en) 1995-09-15 1998-05-05 The Scripps Research Institute Screening methods for the identification of novel antibiotics
WO1997016533A1 (en) 1995-10-31 1997-05-09 The Regents Of The University Of California Mammalian artificial chromosomes and methods of using same
US6022963A (en) 1995-12-15 2000-02-08 Affymetrix, Inc. Synthesis of oligonucleotide arrays using photocleavable protecting groups
US6013440A (en) 1996-03-11 2000-01-11 Affymetrix, Inc. Nucleic acid affinity columns
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US5725838A (en) 1996-05-31 1998-03-10 Resolution Pharmaceuticals, Inc. Radiolabeled D4 receptor ligands
US6057100A (en) 1996-06-07 2000-05-02 Eos Biotechnology, Inc. Oligonucleotide arrays
CA2248784A1 (en) 1996-06-25 1997-12-31 Takeda Chemical Industries, Ltd. Oxazolone derivatives and their use
IL128456A0 (en) 1996-08-12 2000-01-31 Yoshitomi Pharmaceutical Compositions containing a Rho kinase inhibitor
JPH10130269A (ja) 1996-09-04 1998-05-19 Nippon Chemiphar Co Ltd カルボリン誘導体
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
HUP9903330A2 (hu) 1996-11-19 2000-03-28 Amgen Inc. Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények
US6294330B1 (en) 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
WO1998039471A1 (en) 1997-03-07 1998-09-11 Tropix, Inc. Protease inhibtor assay
US5977131A (en) 1997-04-09 1999-11-02 Pfizer Inc. Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents
AU7132998A (en) 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
US6096718A (en) 1997-06-05 2000-08-01 Gene Targeting Corp. Tissue specific adenovirus vectors for breast cancer treatment
SG72827A1 (en) 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
AU8096798A (en) 1997-06-27 1999-01-19 Resolution Pharmaceuticals Inc. Dopamine d4 receptor ligands
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6826296B2 (en) 1997-07-25 2004-11-30 Affymetrix, Inc. Method and system for providing a probe array chip design database
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
US6161776A (en) 1997-08-12 2000-12-19 Nibco Inc. Multi-layered, porous mat turf irrigation apparatus and method
WO1999009217A1 (en) 1997-08-15 1999-02-25 Hyseq, Inc. Methods and compositions for detection or quantification of nucleic acid species
WO1999013313A1 (en) 1997-09-11 1999-03-18 Genovations, Inc. Method of making high density arrays
US6178384B1 (en) 1997-09-29 2001-01-23 The Trustees Of Columbia University In The City Of New York Method and apparatus for selecting a molecule based on conformational free energy
US6465178B2 (en) 1997-09-30 2002-10-15 Surmodics, Inc. Target molecule attachment to surfaces
ES2234169T3 (es) 1997-12-23 2005-06-16 Warner-Lambert Company Llc Compuestos de tiourea, composiciones y procedimientos de tratamiento o prevencion de enfermedades inflamatorias y ateroesclerosis.
JP2002510628A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
WO1999051596A1 (en) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU3210899A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU3118399A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP1071423A1 (en) 1998-04-02 2001-01-31 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU3210799A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6048695A (en) 1998-05-04 2000-04-11 Baylor College Of Medicine Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
ES2374518T3 (es) 1998-08-17 2012-02-17 Senju Pharmaceutical Co., Ltd. Agente para profilaxis y tratamiento de astenopía y pseudomiopía.
IL141724A0 (en) 1998-08-28 2002-03-10 Scios Inc INHIBITORS OF P38-α KINASE
ES2211161T3 (es) 1998-08-28 2004-07-01 Astrazeneca Ab Tieno(2,3-d)pirimidindionas novedosas, procedimiento para su preparacion y uso de las mismas en terapia.
DE69928414T2 (de) 1998-09-18 2006-08-03 Abbott Gmbh & Co. Kg 4-aminopyrrolopyrimidine als kinaseinhibitoren
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6277628B1 (en) 1998-10-02 2001-08-21 Incyte Genomics, Inc. Linear microarrays
IT1303759B1 (it) 1998-11-17 2001-02-23 Dompe Spa Procedimento migliorato per la preparazione di acido 7-azaindolil-3-carbossilico.
US6277489B1 (en) 1998-12-04 2001-08-21 The Regents Of The University Of California Support for high performance affinity chromatography and other uses
US20010001449A1 (en) 1998-12-30 2001-05-24 Thomas R. Kiliany Low-pressure hydrocracking process
KR20020009570A (ko) 1999-03-05 2002-02-01 도리이 신이찌로 니코틴성 아세틸콜린 α4β2 수용체의 활성화 작용을 가진헤테로시클릭 화합물
WO2000055153A1 (en) 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
AR028475A1 (es) 1999-04-22 2003-05-14 Wyeth Corp Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
US6221653B1 (en) 1999-04-27 2001-04-24 Agilent Technologies, Inc. Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids
FR2793793B1 (fr) 1999-05-19 2004-02-27 Adir Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
TWI234557B (en) 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
HK1046402A1 (zh) 1999-06-03 2003-01-10 Basf Aktiengesellschaft Benzothiazinone和benzoxazinone化合物
HK1049154A1 (zh) 1999-07-30 2003-05-02 Abbott Gmbh & Co. Kg 作为酪氨酸激酶抑制剂的2-吡唑啉-5-酮
US6653151B2 (en) 1999-07-30 2003-11-25 Large Scale Proteomics Corporation Dry deposition of materials for microarrays using matrix displacement
WO2001024236A1 (en) 1999-09-27 2001-04-05 Infineon Technologies North America Corp. Semiconductor structures having a capacitor and manufacturing methods
GB9924962D0 (en) 1999-10-21 1999-12-22 Mrc Collaborative Centre Allosteric sites on muscarinic receptors
EP1106603A3 (en) 1999-12-06 2003-11-19 Fuji Photo Film Co., Ltd. DNA chip and reactive solid carrier
US6610688B2 (en) 1999-12-21 2003-08-26 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
NZ519697A (en) 1999-12-22 2004-08-27 Sugen Inc Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
FR2805259B1 (fr) 2000-02-17 2002-03-29 Inst Nat Sante Rech Med Nouveaux derives d'aminoacides n-mercaptoacyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20020061892A1 (en) 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
JP2001278886A (ja) 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd ベンゾオキサジン誘導体及びこれを含有する医薬
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
EP1313736B1 (en) 2000-06-26 2005-07-27 Lilly Icos LLC Condensed pyrazindione derivatives as inhibitors of pde5
HRP20030140A2 (en) 2000-08-31 2003-04-30 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
JP3548566B2 (ja) 2001-02-27 2004-07-28 アストラゼネカ アクチボラグ 医薬製剤
KR100865262B1 (ko) 2001-04-11 2008-10-24 센주 세이야꾸 가부시키가이샤 시각 기능 장애 개선제
AU2002258971A1 (en) 2001-04-24 2002-11-05 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
GB0114417D0 (en) 2001-06-13 2001-08-08 Boc Group Plc Lubricating systems for regenerative vacuum pumps
EP1267111A1 (en) 2001-06-15 2002-12-18 Dsm N.V. Pressurized fluid conduit
US20040171630A1 (en) 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
US7291639B2 (en) 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
UA75425C2 (en) 2001-07-09 2006-04-17 Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
GB0117583D0 (en) 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
US6858860B2 (en) 2001-07-24 2005-02-22 Seiko Epson Corporation Apparatus and method for measuring natural period of liquid
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003037862A1 (en) 2001-10-30 2003-05-08 Nippon Shinyaku Co., Ltd. Amide derivatives and drugs
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
PL371486A1 (en) 2002-02-01 2005-06-13 Astrazeneca Ab Quinazoline compounds
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
US6884889B2 (en) 2002-03-25 2005-04-26 Bristol-Myers Squibb Co. Processes for the preparation of antiviral 7-azaindole derivatives
CA2480317A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
CA2479205A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. Azaindoles as inhibitors of c-jun n-terminal kinases
WO2003087087A2 (en) 2002-04-09 2003-10-23 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
JP4570955B2 (ja) 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
TW200403243A (en) 2002-07-18 2004-03-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US6878887B2 (en) 2002-08-07 2005-04-12 Matsushita Electric Industrial Co., Ltd. Anti-malfunction mechanism for variable output device
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
KR20120104412A (ko) 2002-09-06 2012-09-20 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
EP1558751A4 (en) 2002-09-16 2007-08-22 Plexxikon Inc CRYSTALLINE STRUCTURE OF PROTEIN KINASE PIM-1
US7183241B2 (en) 2002-10-15 2007-02-27 Exxonmobil Research And Engineering Company Long life lubricating oil composition with very low phosphorus content
SE0203654D0 (sv) 2002-12-09 2002-12-09 Astrazeneca Ab New compounds
EP1569647B1 (en) 2002-12-13 2008-08-20 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300120D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
US20050085463A1 (en) 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
BRPI0407181A (pt) 2003-02-03 2006-02-07 Novartis Ag Formulação farmacêutica
TW200418830A (en) 2003-02-14 2004-10-01 Wyeth Corp Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
JP2007524374A (ja) 2003-02-28 2007-08-30 プレキシコン,インコーポレーテッド Pyk2結晶構造および使用
JP4787150B2 (ja) 2003-03-06 2011-10-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Jnk阻害剤
EP1628975A2 (en) 2003-05-16 2006-03-01 Eisai Co., Ltd. Jnk inhibitors
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
US20050164300A1 (en) 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
EP1667983A4 (en) 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
MXPA06003996A (es) 2003-10-08 2006-07-05 Irm Llc Compuestos y composiciones como inhibidores de la proteina cinasa.
DE10357510A1 (de) 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
US7504509B2 (en) 2003-12-19 2009-03-17 Plexxikon, Inc. Compounds and methods for development of Ret modulators
KR101169265B1 (ko) 2003-12-24 2012-08-02 대니스코 에이/에스 단백질
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
GB0403635D0 (en) 2004-02-18 2004-03-24 Devgen Nv Pyridinocarboxamides with improved activity as kinase inhibitors
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
EP1722789A2 (en) 2004-03-08 2006-11-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ddr2 티로신키나아제 활성 저해제
EP2332940B1 (en) 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
AU2005236002A1 (en) 2004-04-02 2005-11-03 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
EP1773305A2 (en) 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
EP1758571A1 (en) 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for therapeutic use
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US20060058339A1 (en) 2004-06-17 2006-03-16 Ibrahim Prabha N Compounds modulating c-kit activity and uses therefor
WO2006004984A1 (en) 2004-06-30 2006-01-12 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of protein kinases
US7140816B2 (en) 2004-07-20 2006-11-28 H&S Tool, Inc. Multi-functional tube milling head
EP1781654A1 (en) 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CA2573573A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US20060024361A1 (en) 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
EP1789393A2 (en) 2004-07-30 2007-05-30 GPC Biotech AG Pyridinylamines
JP4954086B2 (ja) 2004-12-08 2012-06-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 1h−ピロロ[2,3−b]ピリジン
ATE524467T1 (de) 2005-04-25 2011-09-15 Merck Patent Gmbh Neuartige aza-heterozyklen als kinase-inhibitoren
FR2884821B1 (fr) 2005-04-26 2007-07-06 Aventis Pharma Sa Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
WO2007013896A2 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
NZ564065A (en) 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
JP2008507567A (ja) 2005-05-23 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド 非晶性シナカルセト塩酸塩及びその調製
BRPI0611596A2 (pt) 2005-06-21 2010-09-21 Mitsui Chemicals Inc derivado de amina e inseticida contendo o mesmo
TWI473808B (zh) 2005-06-22 2015-02-21 Plexxikon Inc 用於激酶調節的化合物及方法及其適應症
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
US20070218138A1 (en) 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
US7963673B2 (en) 2006-05-30 2011-06-21 Finn Bruce L Versatile illumination system
WO2008058341A1 (en) 2006-11-15 2008-05-22 Cytopia Research Pty Ltd Inhibitors of kinase activity
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
JP2010526848A (ja) 2007-05-11 2010-08-05 エフ.ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
TW200908968A (en) 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
WO2009012791A1 (en) 2007-07-23 2009-01-29 Pharmathen S.A. Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
CA2716947A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
WO2009111278A2 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
CA2716949A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
US8394795B2 (en) 2008-02-29 2013-03-12 Array Biopharma Inc. Pyrazole [3, 4-B] pyridine Raf inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114928A2 (en) * 2009-04-03 2010-10-07 F.Hoffmann-La Roche Ag Compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ABU T. M. SERAJUDDIN: "Solid Dispersion of Poorly Water-Soluble Drugs:Early Promises,Subsequent Problems,and Recent Breakthroughs", 《JOURNAL OF PHARMACEUTICAL SCIENCES》, vol. 88, no. 10, 27 August 1999 (1999-08-27), pages 1058 - 1066 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115991704A (zh) * 2022-12-16 2023-04-21 深圳市新阳唯康科技有限公司 维莫非尼的新晶型、使用新晶型制备的活性药物和药物组合物

Also Published As

Publication number Publication date
EP3281675A1 (en) 2018-02-14
AU2012259422A8 (en) 2013-10-31
AR085279A1 (es) 2013-09-18
TWI558702B (zh) 2016-11-21
BR112013021103A2 (pt) 2020-12-29
EP2678075A1 (en) 2014-01-01
AU2012259422A1 (en) 2013-04-11
ZA201306237B (en) 2017-05-31
NZ614077A (en) 2015-12-24
JP2016153404A (ja) 2016-08-25
JP2014505740A (ja) 2014-03-06
MY163083A (en) 2017-08-15
AU2012259422B2 (en) 2015-04-23
US20140039002A1 (en) 2014-02-06
CA2827708A1 (en) 2012-11-29
WO2012161776A1 (en) 2012-11-29
US8865735B2 (en) 2014-10-21
SG192722A1 (en) 2013-09-30
TW201309694A (zh) 2013-03-01
MX2013009558A (es) 2013-09-06
CN106632314A (zh) 2017-05-10
IL227862A0 (en) 2013-09-30
RU2013143010A (ru) 2015-04-10
KR20140011340A (ko) 2014-01-28
EP2678075A4 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
CN103442767A (zh) 药物活性物质的固体形式
TW201036957A (en) Novel salt 628
KR20120006006A (ko) 프로판-1-술폰산 {3-[5-(4-클로로-페닐)-1H-피롤로[2,3-b]피리딘-3-카르보닐]-2,4-디플루오로-페닐}-아미드 조성물 및 그의 용도
CN116615424A (zh) 经取代的吡唑并嘧啶的固态形式和其用途
EP3143004B1 (en) Amorphous form of apremilast
US20190100519A1 (en) Hydrochloride salt crystal of drug for treating or preventing jak-associated disease and preparation method thereof
JP2008501024A (ja) 混合コクリスタルおよびそれを含んでなる製薬学的組成物
US20240262785A1 (en) Solid Forms, Salts and Polymorphs of Anti-fibrotic Compounds
CN103200821A (zh) 非布索坦的多晶型物
EP3873885A1 (en) Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
CN116514803A (zh) 一种激酶抑制剂的盐晶型和自由碱晶型
HK1237761A (en) Solid forms of a pharmaceutically active substance
HK1237761A1 (en) Solid forms of a pharmaceutically active substance
HK1191890A (en) Solid forms of a pharmaceutically active substance
NZ630486B2 (en) Process for the humanization of animal skim milk and products obtained thereby
EP2832723B1 (en) Stabilised amorphous forms of Saxagliptin
NZ614077B2 (en) Solid forms of a pharmaceutically active substance
WO2013130600A1 (en) Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
CZ2015250A3 (cs) Amorfní formy vemurafenibu
CN103270030B (zh) 吡唑基氨基喹唑啉的氢溴酸盐
CN118414334A (zh) 谷氨酸利那拉生甲磺酸盐的多晶型物
HK40053332A (en) Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
US20070161709A1 (en) Amorphous tamsulosin hydrochloride

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1191890

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20131211